Neovacs is a French biotechnology company focused on active immunotherapy for autoimmune and inflammatory diseases. Using its proprietary technology platform, the company researches and develops Kinoids, drug-candidates which aim to treat disease by inducing an antibody response in the patient.
Neovacs currently focuses its development efforts on two Kinoids:
- TNF-Kinoid is currently developped for Crohn’s disease and Rheumatoid Arthritis
- IFNα-Kinoid is currently developped for the lupus disease
Neovacs has unveiled very exciting clinical data in all three studies - all presented at major scientific meetings.
To date, More than 100 patients have now been treated with a NEOVACS immunotherapy.